menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Do We Need to Temper our Enthusiasm for Incretin-Based Therapy?

close
Do We Need to Temper our Enthusiasm for Incretin-Based Therapy?
RestartResume
Choose a format
Media formats available:
Details
Presenters
Comments
  • Overview

    There have been impressive results with incretin-based therapy for patients with type 2 diabetes: improved A1C, beta-cell preservation and weight loss are some of the benefits. But do healthcare professionals need to temper their enthusiasm for this novel therapy? Join host Dr. Steven Edelman and his guest, medical director of the International Diabetes Center, Park Nicollet Health Services, Dr. Robert Cuddihy, as they discuss whether incretin-based therapy holds promise of a truly disease-modifying therapy.

     

     

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    There have been impressive results with incretin-based therapy for patients with type 2 diabetes: improved A1C, beta-cell preservation and weight loss are some of the benefits. But do healthcare professionals need to temper their enthusiasm for this novel therapy? Join host Dr. Steven Edelman and his guest, medical director of the International Diabetes Center, Park Nicollet Health Services, Dr. Robert Cuddihy, as they discuss whether incretin-based therapy holds promise of a truly disease-modifying therapy.

     

     

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/25/20